News &amp; Updates

Use of metformin provides a protective benefit against the development of oesophageal squamous cell carcinoma (ESCC), a recent study has shown.

Metformin use reduces risk of oesophageal squamous cell carcinoma

6MWT helps pinpoint ideal candidates for lung resection surgery of NSCLC

A six-minute walk test (6MWT) provides additional information necessary to identify nonsmall cell lung cancer (NSCLC) patients who are optimal candidates for lung resection surgery, as shown in a recent study.

6MWT helps pinpoint ideal candidates for lung resection surgery of NSCLC

Abiraterone acetate, enzalutamide up death risk in older prostate cancer patients with CVDs

Treatment with abiraterone acetate (AA) or enzalutamide (ENZ) may lead to excess short-term mortality in elderly prostate cancer with pre-existing cardiovascular diseases (CVDs), reports a recent study.

Abiraterone acetate, enzalutamide up death risk in older prostate cancer patients with CVDs

Red cell distribution width not linked to survival outcomes in colorectal cancer

High red cell distribution width (RDW) does not seem to affect survival outcomes in patients with colorectal cancer (CRC), reports a recent study.

Red cell distribution width not linked to survival outcomes in colorectal cancer

Secondary surgical cytoreduction does not improve survival in recurrent ovarian cancer

Secondary surgical cytoreduction is feasible, with acceptable postoperative morbidity, but falls short of improving overall survival in patients with platinum-sensitive, recurrent ovarian cancer, according to study.

Secondary surgical cytoreduction does not improve survival in recurrent ovarian cancer

Reassess drugs affecting balance, perception in multiple myeloma patients, says study

Polypharmacy cannot be avoided in patients with multiple myeloma, but medications affecting balance and perception must be reconsidered in these individuals, suggests a study.

Reassess drugs affecting balance, perception in multiple myeloma patients, says study

TAPUR study may identify new biomarker-based therapies for heavily-pretreated CRC

03 Feb 2020 by

The TAPUR study – the first clinical trial conducted by the American Society of Clinical Oncology (ASCO) – may help identify new biomarker-based therapies for patients with heavily-pretreated colorectal cancer (CRC) who have HER2-positive or BRAF^V600E-mutated tumours or a high tumour mutation burden (TMB) and have no standard treatment options.

TAPUR study may identify new biomarker-based therapies for heavily-pretreated CRC